WINT Stock Overview
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Windtree Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.16 |
| 52 Week High | US$35.10 |
| 52 Week Low | US$4.78 |
| Beta | 0.59 |
| 1 Month Change | -20.43% |
| 3 Month Change | -35.99% |
| 1 Year Change | -83.73% |
| 3 Year Change | -99.75% |
| 5 Year Change | -99.96% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)
Dec 06Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions
Jul 06Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable
Jun 09
Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?
Feb 09Shareholder Returns
| WINT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -28.6% | 1.0% | 1.2% |
| 1Y | -83.7% | 0.7% | 24.9% |
Price Volatility
| WINT volatility | |
|---|---|
| WINT Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: WINT's share price has been volatile over the past 3 months.
Volatility Over Time: WINT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 20 | Craig Fraser | windtreetx.com |
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.
Windtree Therapeutics, Inc. Fundamentals Summary
| WINT fundamental statistics | |
|---|---|
| Market cap | US$2.90m |
| Earnings (TTM) | -US$20.29m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs WINT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WINT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.29m |
| Earnings | -US$20.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -39.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 449.2% |
How did WINT perform over the long term?
See historical performance and comparison